Clinical Trial Update: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of 20 mg sumatriptan intranasal powder delivered with a bidirectional device compared to 100 mg sumatriptan t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Sumatriptan Tablet (sumatriptan)
• Sumatriptan intranasal powder (sumatriptan)

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Migraine, Headaches | Phase 3 | Status: COMPLETED | Results posted: 2017-03-14